# Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis

> **NCT04725136** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kang Stem Biotech Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** FURESTEM-AD inj

## Key facts

- **NCT ID:** NCT04725136
- **Lead sponsor:** Kang Stem Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-27
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725136, "Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04725136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*